InnoCare Pharma (09969) Sets 25 March 2026 Board Meeting to Approve FY2025 Results

Bulletin Express03-12

InnoCare Pharma Limited (Stock code: 09969) announced that its Board of Directors will convene on Wednesday, 25 March 2026. The primary agenda is to consider and approve the consolidated annual results for the financial year ended 31 December 2025, along with related matters surrounding their publication.

The notice, dated 12 March 2026, was issued under the name of Chairperson and Executive Director Dr. Jisong Cui. The current Board comprises two executive directors—Dr. Jisong Cui and Dr. Renbin Zhao—two non-executive directors—Dr. Yigong Shi and Mr. Ronggang Xie—and three independent non-executive directors—Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187703824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187703824","market":"hk","top_or_hot":-1,"title":"InnoCare Pharma (09969) Sets 25 March 2026 Board Meeting to Approve FY2025 Results","media":"Bulletin Express","content":"<p>InnoCare Pharma Limited (Stock code: 09969) announced that its Board of Directors will convene on Wednesday, 25 March 2026. The primary agenda is to consider and approve the consolidated annual results for the financial year ended 31 December 2025, along with related matters surrounding their publication.</p>\n<p>The notice, dated 12 March 2026, was issued under the name of Chairperson and Executive Director Dr. Jisong Cui. The current Board comprises two executive directors—Dr. Jisong Cui and Dr. Renbin Zhao—two non-executive directors—Dr. Yigong Shi and Mr. Ronggang Xie—and three independent non-executive directors—Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma (09969) Sets 25 March 2026 Board Meeting to Approve FY2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma (09969) Sets 25 March 2026 Board Meeting to Approve FY2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>InnoCare Pharma Limited (Stock code: 09969) announced that its Board of Directors will convene on Wednesday, 25 March 2026. The primary agenda is to consider and approve the consolidated annual results for the financial year ended 31 December 2025, along with related matters surrounding their publication.</p>\n<p>The notice, dated 12 March 2026, was issued under the name of Chairperson and Executive Director Dr. Jisong Cui. The current Board comprises two executive directors—Dr. Jisong Cui and Dr. Renbin Zhao—two non-executive directors—Dr. Yigong Shi and Mr. Ronggang Xie—and three independent non-executive directors—Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1187703824","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187703824","pubTimestamp":1773305119,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"InnoCare Pharma Limited (Stock code: 09969) announced that its Board of Directors will convene on Wednesday, 25 March 2026. The primary agenda is to consider and approve the consolidated annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华"},"translate_title":"诺诚健华医药(09969)定于2026年3月25日召开董事会批准2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1},"content_text":"InnoCare Pharma Limited (Stock code: 09969) announced that its Board of Directors will convene on Wednesday, 25 March 2026. The primary agenda is to consider and approve the consolidated annual results for the financial year ended 31 December 2025, along with related matters surrounding their publication.\nThe notice, dated 12 March 2026, was issued under the name of Chairperson and Executive Director Dr. Jisong Cui. The current Board comprises two executive directors—Dr. Jisong Cui and Dr. Renbin Zhao—two non-executive directors—Dr. Yigong Shi and Mr. Ronggang Xie—and three independent non-executive directors—Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187703824","isCrawlerRequest":true}